20 mg in female arousal studies Subcutaneous injection: 0.75 mg, 1.25 mg, and 1.75 mg in Phase 2-3 female HSDD trials FDA-approved dose: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity Important: These are doses from completed clinical trials
Accessed at pubmed.ncbi.nlm.nih.gov/33567185
Benefits Want more from your workouts
Waitlist members get first access the moment either is cleared for prescription
The peptide is not FDA-approved for vitiligo treatment and should not replace evidence-based therapies (topical corticosteroids, calcineurin inhibitors, JAK inhibitors, or phototherapy)
Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and [PMID: 33156405] Laboratory literature summary: Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems